Next Article in Journal / Special Issue
New Tools for Molecular Therapy of Hepatocellular Carcinoma
Previous Article in Journal / Special Issue
Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma
Open AccessReview

Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma

Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Stephen L. Chan
Diseases 2015, 3(4), 306-324; https://doi.org/10.3390/diseases3040306
Received: 28 August 2015 / Revised: 4 October 2015 / Accepted: 21 October 2015 / Published: 28 October 2015
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death. In patients with advanced or unresectable HCC, there are few treatment options. Conventional chemotherapy has limited benefits. Sorafenib, a multi-kinase inhibitor, improves survival, but options for patients intolerant of or progressing on sorafenib are limited. There has been much interest in recent years in molecular therapeutic targets and drug development for HCC. One of the more promising molecular targets in HCC is the cellular-mesenchymal-epithelial transition (c-MET) factor receptor. Encouraging phase II data on two c-MET inhibitors, tivantinib and cabozantinib, has led to phase III trials. This review describes the c-MET/hepatocyte growth factor (HGF) signalling pathway and its relevance to HCC, and discusses the preclinical and clinical trial data for inhibitors of this pathway in HCC. View Full-Text
Keywords: hepatocellular carcinoma (HCC); c-MET; hepatocyte growth factor (HGF); c-MET inhibitor; tivantinib; cabozantinib hepatocellular carcinoma (HCC); c-MET; hepatocyte growth factor (HGF); c-MET inhibitor; tivantinib; cabozantinib
Show Figures

Figure 1

MDPI and ACS Style

Lee, J.J.X.; Chan, J.J.; Choo, S.P. Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma. Diseases 2015, 3, 306-324.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop